Robert Edward Dempski

age ~50

from Holden, MA

Get Report

Also known as:

Robert E Dempski
Rob E Dempski
Bob E Dempski
Robert I
Danielle Franz

Phone and address:: 37 Kris Alan Dr, Holden, MA 01520

Connected to:

Robert Dempski Phones & Addresses

37 Kris Alan Dr, Holden, MA 01520
Worcester, MA
Newfoundland, PA
Pasadena, CA
1629 Arran Way, Dresher, PA 19025
Somerville, MA
Pocono Pines, PA

Work

Company:

Worcester polytechnic institute
Mar 2015
Position:

Associate professor

Education

Degree:

Doctorates, Doctor of Philosophy
School / High School:

Massachusetts Institute of Technology
1999 to 2003
Specialities:

Chemistry

Skills

Biochemistry • Protein Chemistry • Molecular Biology • Characterization • Protein Expression • Life Sciences • Protein Purification • Biophysics • Cell Biology • Lifesciences • Chemistry • Science

Languages

English

Industries

Research

Resumes

Associate Professor

view source

Location:

Worcester, MA

Industry:

Research

Work:

Worcester Polytechnic Institute
Associate Professor
Worcester Polytechnic Institute Oct 2009 - Mar 2015
Assistant Professor
Max Planck Institute For Biophysics Jun 2003 - Sep 2009
Post Doctoral Fellow

Education:

Massachusetts Institute of Technology 1999 - 2003
Doctorates, Doctor of Philosophy, Chemistry Caltech 1997 - 1999
Bucknell University 1993 - 1997
Bachelors, Bachelor of Science, Biochemistry

Skills:

Biochemistry
Protein Chemistry
Molecular Biology
Characterization
Protein Expression
Life Sciences
Protein Purification
Biophysics
Cell Biology
Lifesciences
Chemistry
Science

Languages:

English

License Records

Robert Edward Dempski

Address:

Dresher, PA 19025

License #:

RP022679L - Expired

Category:

Pharmacy

Type:

Pharmacist

Us Patents

Mutant Channelrhodopsin 2
view source
US Patent:

20130281379, Oct 24, 2013
Filed:

Sep 8, 2011
Appl. No.:

13/821353
Inventors:

Ernst Bamberg - Kelkheim, DE
Christian Bamann - Frankfurt, DE
Sonja Kleinlogel - Steinbach/Ts., CH
Phillip Wood - Schmelz, DE
Robert E. Dempski - Worcester MA, US
Assignee:

Max-Planck-Gesellschaft zur Foerderung der Wissenschaftern e.V. - Muenchen
International Classification:

C07K 14/405
G01N 33/68
US Classification:

514 174, 530350, 536 237, 4353201, 435325, 435365, 435352, 435369, 435358, 435350, 435375, 506 10
Abstract:

The invention relates to mutant channelrhodopsins having improved properties, nucleic acid constructs encoding same, expression vectors carrying the nucleic acid construct, cells comprising said nucleic acid construct or expression vector, and their respective uses.

Sustained Release Indomethacin
view source
US Patent:

41736265, Nov 6, 1979
Filed:

Dec 11, 1978
Appl. No.:

5/968608
Inventors:

Robert E. Dempski - Dresher PA
Gunvant N. Mehta - Lansdale PA
Joseph C. Saboe - Norristown PA
Assignee:

Merck & Co., Inc. - Rahway NJ
International Classification:

A61K 922
A61K 948
US Classification:

424 19
Abstract:

A sustained release indomethacin pharmaceutical product is provided that utilizes a pellet formulation encapsulated in a hard gelatin capsule. A portion of the pellets is uncoated for immediate and rapid release of indomethacin for elevating the plasma level. The remainder of the pellets are coated with a polymer to sustain the plasma level. The uncoated and coated pellets may be mixed with non-medicated pellets as a capsule filler.

Controlled Release Combination Of Carbidopa/Levodopa
view source
US Patent:

49007556, Feb 13, 1990
Filed:

Feb 24, 1989
Appl. No.:

7/315057
Inventors:

Robert E. Dempski - Dresher PA
Edward C. Scholtz - King of Prussia PA
Donald W. Nibbelink - Lansdale PA
Scott A. Reines - New Hope PA
Assignee:

Merck & Co. - Rahway NJ
International Classification:

A61K 920
A61K 922
A61K 926
US Classification:

424469
Abstract:

A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levidopa combinations presently employed.

Methyldopa Composition
view source
US Patent:

44041934, Sep 13, 1983
Filed:

Oct 9, 1981
Appl. No.:

6/309956
Inventors:

Robert E. Dempski - Dresher PA
Joseph L. O'Neill - Lansdale PA
Assignee:

Merck & Co., Inc. - Rahway NJ
International Classification:

A61K 31195
A61K 31715
US Classification:

424176
Abstract:

An aqueous suspension containing methyldopa and sucrose is disclosed. This composition is an oral dosage form for treating hypertension that is bioavailable.

Controlled Release Combination Of Carbidopa/Levodopa
view source
US Patent:

49834002, Jan 8, 1991
Filed:

Dec 1, 1989
Appl. No.:

7/444222
Inventors:

Robert E. Dempski - Dresher PA
Edward C. Scholtz - King of Prussia PA
Donald W. Nibbelink - Lansdale PA
Scott A. Reines - New Hope PA
Assignee:

Merck & Co., Inc. - Rahway NJ
International Classification:

A61K 922
A61K 926
A61K 3178
US Classification:

424469
Abstract:

A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levodopa combination presently employed.

Controlled Release Combination Of Carbidopa/Levodopa
view source
US Patent:

48329576, May 23, 1989
Filed:

Jul 25, 1988
Appl. No.:

7/223861
Inventors:

Robert E. Dempski - Dresher PA
Edward C. Scholtz - King of Prussia PA
Donald W. Nibbelink - Lansdale PA
Scott A. Reines - New Hope PA
Assignee:

Merck & Co., Inc. - Rahway NJ
International Classification:

A61K 920
A61K 922
A61K 926
US Classification:

424469
Abstract:

A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levodopa combinations presently employed.